Okairos (Switzerland) a biopharmaceutical company using adenovirus-based technology to focus on T-cell vaccines has closed a €7.2M Series A financing. The deal was led by Life Science Partners and Biomedinvest and was joined by the Novartis Venture Fund.
Okairos AG: Series A €7.2M
April 2, 2007
Leave a Comment » | 
I - Series A, R - INTERNATIONAL, X - Vaccines | 
Permalink
Posted by arubenstein
AlphaVax, Inc.: Series E $12.65M
February 20, 2007AlphaVax (Durham, NC) a developer of vaccine products for infectious diseases (influenza & cytomegalovirus lead), biodefense and cancer, has raised approximately $12.65 million in Series E funding. Investors have not been disclosed.
Leave a Comment » | 
I - Series E, R - SOUTH EAST, X - Cytomegalovirus, X - Vaccines | 
Permalink
Posted by arubenstein
Juvaris BioTherapeutics Inc.: Series A $6M
January 18, 2007Juvaris BioTherapeutics (Pleasanton, CA) an oncology and anti-infective vaccine platform technology closed on $6M of a $12M Series A led by Kleiner Perkins.
Leave a Comment » | 
I - Series A, R - WEST, X - Vaccines | 
Permalink
Posted by arubenstein
Variation Bio, Inc.: Series A $35.7M
January 17, 2007Variation Biotechnologies (Ottawa, Canada) a maker of vaccines for infectious diseases, has raised US$35.7M in Series A funding. The deal was lead by Clarus Ventures with participation from Arch Venture Partners and 5AM Ventures.
Leave a Comment » | I - Series A, R - INTERNATIONAL, X - Vaccines | Permalink
Posted by arubenstein
